1. Home
  2. MHF vs BNR Comparison

MHF vs BNR Comparison

Compare MHF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

N/A

Current Price

$6.39

Market Cap

152.3M

Sector

Finance

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$14.44

Market Cap

126.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MHF
BNR
Founded
1988
2014
Country
United States
China
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.3M
126.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MHF
BNR
Price
$6.39
$14.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.8K
52.1K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
4.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.35
$6.79
52 Week High
$7.55
$41.72

Technical Indicators

Market Signals
Indicator
MHF
BNR
Relative Strength Index (RSI) 22.41 70.47
Support Level N/A $8.91
Resistance Level $7.04 $18.59
Average True Range (ATR) 0.09 1.33
MACD -0.03 0.39
Stochastic Oscillator 16.75 96.89

Price Performance

Historical Comparison
MHF
BNR

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: